Skip to main content
. 2019 Oct 1;26(10):915–930. doi: 10.5551/jat.48405

Fig. 1.

Fig. 1.

Rivaroxaban treatment significantly improved the survival rate

The survival rate of the rivaroxaban-treated group improved significantly compared with the non-treated ICM model (rivaroxaban group, n = 49; ICM model group, n = 126). **p < 0.01.